Please use this identifier to cite or link to this item:
|Title:||Therapeutic Monoclonal Antibodies: Attractions and Challenges|
|Keywords:||Monoclonal antibodies;Mab technologies;Transgeincs|
|Abstract:||Due to the technological advances made during the past decade, therapeutic monoclonal antibodies (MAbs) now represent an important and growing class of bio-therapeutics. Sales of MAbs are increasing rapidly from virtually nil in 1996 to potentially over $ 1 billion in 2001. With the potential new targets resulting from genomics and with methods now in place to make fully human antibodies, the potential of antibodies as valuable therapeutics in oncology, inflammation and cardiovascular disease is being fully realised. There are 235 MAbs under different stages of development. More than 100 clinical trials are in progress, 14 of them in phase III (mostly for cancer diagnosis and therapy). To meet the increased demand of the monoclonals, worldwide manufacturing capacity for MAbs must increase dramatically, during the next few years, if the industry segment is to avoid a manufacturing bottleneck. Many novel expression strategies are being evaluated to increase the production capacity. Factors including molecular fidelity and cost of products will be critical in the selection of the expression systems.|
|ISSN:||0975-0967 (Online); 0972-5849 (Print)|
|Appears in Collections:|| IJBT Vol.01(1) [January 2002]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.